αž‘αžΈαž•αŸ’αžŸαžΆαžš
Dr Reddy's Laboratories Ltd
1,176.25β‚Ή
29 មេសអ, 4:01:22 PM αž˜αŸ‰αŸ„αž„β€‹αžŸαž€αž› +5:30 · INR · BOM · αžŸαŸαž…αž€αŸ’αžŠαžΈαž”αŸ’αžšαž€αžΆαžŸαž˜αž·αž“αž‘αž‘αž½αž›αžαž»αžŸαžαŸ’αžšαžΌαžœ
αž—αžΆαž‚β€‹αž αŸŠαž»αž“αž˜αžΌαž›αž”αžαŸ’αžšαžŠαŸ‚αž›αž”αžΆαž“αž…αž»αŸ‡αž”αž‰αŸ’αž‡αžΈαž“αŸ… INαž˜αžΆαž“αž‘αžΈαžŸαŸ’αž“αžΆαž€αŸ‹αž€αžΆαžšαž€αžŽαŸ’αžŠαžΆαž›αž“αŸ… IN
αž”αž·αž‘αž–αžΈαž˜αž»αž“
1,199.70β‚Ή
αž…αž“αŸ’αž›αŸ„αŸ‡αžαŸ’αž„αŸƒαž“αŸαŸ‡
1,168.65β‚Ή - 1,210.00β‚Ή
αž…αž“αŸ’αž›αŸ„αŸ‡αž˜αž½αž™αž†αŸ’αž“αžΆαŸ†αž…αž»αž„αž€αŸ’αžšαŸ„αž™
1,025.90β‚Ή - 1,420.20β‚Ή
αžŠαžΎαž˜β€‹αž‘αž»αž“β€‹αž‘αžΈαž•αŸ’αžŸαžΆαžš
977.83Β αž”αŸŠαžΈαž›αžΆαž“ INR
αž‘αŸ†αž αŸ†αž‡αž½αž‰αžŠαžΌαžšαž˜αž’αŸ’αž™αž˜
123.18Β αž–αžΆαž“αŸ‹
αž’αž“αž»αž”αžΆαž P/E
18.26
αž‘αž·αž“αŸ’αž“αž•αž›β€‹αž—αžΆαž‚αž›αžΆαž—
0.68%
αž€αžΆαžšαžŠαŸ„αŸ‡αžŠαžΌαžšαž…αž˜αŸ’αž”αž„
NSE
αž–αŸαžαŸŒαž˜αžΆαž“αž‘αžΈαž•αŸ’αžŸαžΆαžš
.INX
0.00%
SPOT
0.46%
.DJI
0.00%
.DJI
0.00%
GM
0.042%
.INX
0.00%
.DJI
0.00%
αž αž·αžšαž‰αŸ’αž‰αžœαžαŸ’αžαž»
αžšαž”αžΆαž™αž€αžΆαžšαžŽαŸαž”αŸ’αžšαžΆαž€αŸ‹αž…αŸ†αžŽαžΌαž›
αž…αŸ†αžŽαžΌαž›
αž…αŸ†αžŽαžΌαž›αžŸαž»αž‘αŸ’αž’
(INR)αž’αŸ’αž“αžΌ 2024αž€αžΆαžšαž•αŸ’αž›αžΆαžŸαŸ‹αž”αŸ’αžŠαžΌαžšαžαžΆαž˜β€‹αž†αŸ’αž“αžΆαŸ†
αž…αŸ†αžŽαžΌαž›
83.59Β αž”αŸŠαžΈαž›αžΆαž“15.85%
αž…αŸ†αžŽαžΆαž™αž”αŸ’αžšαžαž·αž”αžαŸ’αžαž·αž€αžΆαžš
30.34Β αž”αŸŠαžΈαž›αžΆαž“19.95%
αž…αŸ†αžŽαžΌαž›αžŸαž»αž‘αŸ’αž’
14.13Β αž”αŸŠαžΈαž›αžΆαž“2.49%
αž”αŸ’αžšαžΆαž€αŸ‹αž…αŸ†αžŽαŸαž‰αžŸαž»αž‘αŸ’αž’
16.91-11.51%
β€‹αž…αŸ†αžŽαžΌαž›αžŸαž»αž‘αŸ’αž’β€‹αž€αŸ’αž“αž»αž„αž˜αž½αž™αž—αžΆαž‚αž αŸŠαž»αž“
16.941.81%
αž…αŸ†αžŽαžΌαž›αžŸαž»αž‘αŸ’αž’αž˜αž»αž“αž€αžΆαžšαž”αŸ’αžšαžΆαž€αŸ‹ αž–αž“αŸ’αž’ αž€αžΆαžšαžšαŸ†αž›αžŸαŸ‹ αž“αž·αž„αž€αžΆαžšαž€αžΆαžαŸ‹αžšαŸ†αž›αžŸαŸ‹
23.43Β αž”αŸŠαžΈαž›αžΆαž“13.31%
αž’αžαŸ’αžšαžΆαž–αž“αŸ’αž’αžŠαŸ‚αž›αž˜αžΆαž“αž”αŸ’αžšαžŸαž·αž‘αŸ’αž’αž—αžΆαž–
25.10%β€”
αž‘αŸ’αžšαž–αŸ’αž™αžŸαžšαž»αž”
αž€αžΆαžšαž‘αž‘αž½αž›αžαž»αžŸαžαŸ’αžšαžΌαžœαžŸαžšαž»αž”
(INR)αž’αŸ’αž“αžΌ 2024αž€αžΆαžšαž•αŸ’αž›αžΆαžŸαŸ‹αž”αŸ’αžŠαžΌαžšαžαžΆαž˜β€‹αž†αŸ’αž“αžΆαŸ†
αžŸαžΆαž…αŸ‹αž”αŸ’αžšαžΆαž€αŸ‹ αž“αž·αž„αž€αžΆαžšαžœαž·αž“αž·αž™αŸ„αž‚αžšαž™αŸˆαž–αŸαž›αžαŸ’αž›αžΈ
59.92Β αž”αŸŠαžΈαž›αžΆαž“-17.41%
αž‘αŸ’αžšαž–αŸ’αž™αžŸαžšαž»αž”
481.06Β αž”αŸŠαžΈαž›αžΆαž“29.02%
αž€αžΆαžšαž‘αž‘αž½αž›αžαž»αžŸαžαŸ’αžšαžΌαžœαžŸαžšαž»αž”
159.49Β αž”αŸŠαžΈαž›αžΆαž“51.91%
αž˜αžΌαž›β€‹αž’αž“αžŸαžšαž»αž”
321.56Β αž”αŸŠαžΈαž›αžΆαž“β€”
αž—αžΆαž‚αž αŸŠαž»αž“β€‹αž˜αž·αž“β€‹αž‘αžΆαž“αŸ‹αž”αžΆαž“αž”αž„αŸ‹
833.12Β αž›αžΆαž“β€”
αžαž˜αŸ’αž›αŸƒαž’αŸ€αž”αž“αžΉαž„αžŸαŸ€αžœαž—αŸ…
3.15β€”
αž•αž›αž…αŸ†αžŽαŸαž‰αž›αžΎαž‘αŸ’αžšαž–αŸ’αž™
9.88%β€”
αž•αž›αž…αŸ†αžŽαŸαž‰αž›αžΎαžŠαžΎαž˜αž‘αž»αž“
12.81%β€”
αž€αžΆαžšαž”αŸ’αžšαŸ‚αž”αŸ’αžšαž½αž›β€‹αžŸαžΆαž…αŸ‹αž”αŸ’αžšαžΆαž€αŸ‹αžŸαž»αž‘αŸ’αž’
(INR)αž’αŸ’αž“αžΌ 2024αž€αžΆαžšαž•αŸ’αž›αžΆαžŸαŸ‹αž”αŸ’αžŠαžΌαžšαžαžΆαž˜β€‹αž†αŸ’αž“αžΆαŸ†
αž…αŸ†αžŽαžΌαž›αžŸαž»αž‘αŸ’αž’
14.13Β αž”αŸŠαžΈαž›αžΆαž“2.49%
αžŸαžΆαž…αŸ‹αž”αŸ’αžšαžΆαž€αŸ‹αž–αžΈαž”αŸ’αžšαžαž·αž”αžαŸ’αžαž·αž€αžΆαžš
6.62Β αž”αŸŠαžΈαž›αžΆαž“39.75%
αžŸαžΆαž…αŸ‹αž”αŸ’αžšαžΆαž€αŸ‹αž–αžΈαž€αžΆαžšαžœαž·αž“αž·αž™αŸ„αž‚
-5.46Β αž”αŸŠαžΈαž›αžΆαž“66.27%
αžŸαžΆαž…αŸ‹αž”αŸ’αžšαžΆαž€αŸ‹αž–αžΈαž αž·αžšαž‰αŸ’αž‰β€‹αž”αŸ’αž”αž‘αžΆαž“
590.00Β αž›αžΆαž“-88.83%
αž€αžΆαžšαž”αŸ’αžšαŸ‚αž”αŸ’αžšαž½αž›β€‹αžŸαžΆαž…αŸ‹αž”αŸ’αžšαžΆαž€αŸ‹αžŸαž»αž‘αŸ’αž’
1.75Β αž”αŸŠαžΈαž›αžΆαž“129.12%
αž›αŸ†αž αžΌαžšαžŸαžΆαž…αŸ‹αž”αŸ’αžšαžΆαž€αŸ‹αž‘αŸ†αž“αŸαžš
-382.75Β αž›αžΆαž“90.46%
αž’αŸ†αž–αžΈ
Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology. Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to other less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe. By 2007, Dr. Wikipedia
αž”αžΆαž“αž”αž„αŸ’αž€αžΎαžαž‘αžΎαž„
1984
αž€αžΆαžšαž·αž™αžΆαž›αŸαž™β€‹αž€αžŽαŸ’αžŠαžΆαž›
αžαŸ†αž”αž“αŸ‹β€‹αž”αžŽαŸ’αžŠαžΆαž‰
αž”αž»αž‚αŸ’αž‚αž›αž·αž€
27,048
αžŸαŸ’αžœαŸ‚αž„αžšαž€β€‹αž…αŸ’αžšαžΎαž“αž‘αŸ€αž
αž’αŸ’αž“αž€αž’αžΆαž…αž…αžΆαž”αŸ‹αž’αžΆαžšαž˜αŸ’αž˜αžŽαŸαž›αžΎ
αž”αž‰αŸ’αž‡αžΈαž“αŸαŸ‡αžαŸ’αžšαžΌαžœαž”αžΆαž“αž”αž„αŸ’αž€αžΎαžαž‘αžΎαž„αž–αžΈαž€αžΆαžšαžŸαŸ’αžœαŸ‚αž„αžšαž€αžαŸ’αž˜αžΈαŸ— αž˜αžΌαž›αž”αžαŸ’αžšαžŠαŸ‚αž›αž”αžΆαž“αžαžΆαž˜αžŠαžΆαž“ αž“αž·αž„αžŸαž€αž˜αŸ’αž˜αž—αžΆαž–αž•αŸ’αžŸαŸαž„αž‘αŸ€αžαŸ” αžŸαŸ’αžœαŸ‚αž„αž™αž›αŸ‹αž”αž“αŸ’αžαŸ‚αž˜

αž‘αž·αž“αŸ’αž“αž“αŸαž™ αž“αž·αž„αž–αŸαžαŸŒαž˜αžΆαž“αž‘αžΆαŸ†αž„αž’αžŸαŸ‹αžαŸ’αžšαžΌαžœαž”αžΆαž“αž•αŸ’αžαž›αŸ‹αž‡αžΌαž“ β€œαžŠαžΌαž…αžŠαŸ‚αž›αž˜αžΆαž“β€ αžŸαž˜αŸ’αžšαžΆαž”αŸ‹αžαŸ‚αž‚αŸ„αž›αž”αŸ†αžŽαž„αž–αŸαžαŸŒαž˜αžΆαž“αž•αŸ’αž‘αžΆαž›αŸ‹αžαŸ’αž›αž½αž“αž”αŸ‰αž»αžŽαŸ’αžŽαŸ„αŸ‡ αž αžΎαž™αž˜αž·αž“αž˜αžΆαž“αž‚αŸ„αž›αž”αŸ†αžŽαž„αž•αŸ’αžŠαž›αŸ‹β€‹αž‡αžΆαžŠαŸ†αž”αžΌαž“αŸ’αž˜αžΆαž“αž•αŸ’αž“αŸ‚αž€αž αž·αžšαž‰αŸ’αž‰αžœαžαŸ’αžαž» αž¬αž€αŸαžŸαž˜αŸ’αžšαžΆαž”αŸ‹αž‚αŸ„αž›αž”αŸ†αžŽαž„αž–αžΆαžŽαž·αž‡αŸ’αž‡αž€αž˜αŸ’αž˜αž¬αž€αžΆαžšαžœαž·αž“αž·αž™αŸ„αž‚ αž–αž“αŸ’αž’ αž…αŸ’αž”αžΆαž”αŸ‹ αž‚αžŽαž“αŸαž™αŸ’αž™ αž¬αžŠαŸ†αž”αžΌαž“αŸ’αž˜αžΆαž“αž•αŸ’αžŸαŸαž„αž‘αŸ€αžαž‘αžΎαž™αŸ” Google αž˜αž·αž“αž˜αŸ‚αž“αž‡αžΆαž‘αžΈαž”αŸ’αžšαžΉαž€αŸ’αžŸαžΆαž•αŸ’αž“αŸ‚αž€αžœαž·αž“αž·αž™αŸ„αž‚ αž¬αž‘αžΈαž”αŸ’αžšαžΉαž€αŸ’αžŸαžΆαž•αŸ’αž“αŸ‚αž€αž αž·αžšαž‰αŸ’αž‰αžœαžαŸ’αžαž»αž‘αŸ αž“αž·αž„αž˜αž·αž“αž”αž‰αŸ’αž…αŸαž‰αž‘αžŸαŸ’αžŸαž“αŸˆ αž€αžΆαžšαžŽαŸ‚αž“αžΆαŸ† αž¬αž‚αŸ†αž“αž·αžαž™αŸ„αž”αž›αŸ‹αž–αžΆαž€αŸ‹αž–αŸαž“αŸ’αž’αž“αžΉαž„αž€αŸ’αžšαž»αž˜αž αŸŠαž»αž“αžŽαžΆαž˜αž½αž™αžŠαŸ‚αž›αž˜αžΆαž“αž€αŸ’αž“αž»αž„αž”αž‰αŸ’αž‡αžΈαž“αŸαŸ‡ αž¬αž˜αžΌαž›αž”αžαŸ’αžšαžŽαžΆαž˜αž½αž™αžŠαŸ‚αž›αž…αŸαž‰αžŠαŸ„αž™αž€αŸ’αžšαž»αž˜αž αŸŠαž»αž“αž‘αžΆαŸ†αž„αž“αŸ„αŸ‡αžŠαŸ‚αžšαŸ” αžŸαžΌαž˜αž–αž·αž‚αŸ’αžšαŸ„αŸ‡αž‡αžΆαž˜αž½αž™αžˆαŸ’αž˜αž½αž‰αž€αžŽαŸ’αžαžΆαž› αž¬αžαŸ†αžŽαžΆαž„αž•αŸ’αž“αŸ‚αž€αž αž·αžšαž‰αŸ’αž‰αžœαžαŸ’αžαž»αžšαž”αžŸαŸ‹αž’αŸ’αž“αž€ αžŠαžΎαž˜αŸ’αž”αžΈαž•αŸ’αž‘αŸ€αž„αž•αŸ’αž‘αžΆαžαŸ‹αžαž˜αŸ’αž›αŸƒαž˜αž»αž“αž“αžΉαž„αž”αŸ’αžšαžαž·αž”αžαŸ’αžαž·αž€αžΆαžšαž‡αž½αž‰αžŠαžΌαžšαžŽαžΆαž˜αž½αž™αŸ” αžŸαŸ’αžœαŸ‚αž„αž™αž›αŸ‹αž”αž“αŸ’αžαŸ‚αž˜
αž€αŸαž˜αžΆαž“β€‹αž’αŸ’αž“αž€β€‹αžŸαŸ’αžœαŸ‚αž„αžšαž€β€‹αžŠαŸ‚αžš
αžŸαŸ’αžœαŸ‚αž„αžšαž€
αžŸαž˜αŸ’αž’αžΆαžβ€‹αž€αžΆαžšβ€‹αžŸαŸ’αžœαŸ‚αž„αžšαž€
αž”αž·αž‘β€‹αž€αžΆαžšβ€‹αžŸαŸ’αžœαŸ‚αž„αžšαž€
αž€αž˜αŸ’αž˜αžœαž·αž’αžΈ Google
αž˜αŸ‰αžΊαž“αž»αž™αžŠαžΎαž˜